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Background: Fluralaner is a potent insecticide and acaricide with rapid and persistent efficacy. This study measured
the efficacy of fluralaner flavored chews (Bravecto®, Merck Animal Health) administered to dogs against adult
Ctenocephalides felis felis and egg production.
Methods: Twelve purpose-bred dogs were randomly allocated to two groups of six dogs each. Dogs in treatment
group 1 were administered a single fluralaner flavored chew to achieve a minimum dose of at least 25 mg/kg while
treatment group 2 served as untreated controls. On Days −2, 28, 56, 84, 91, 98, 105, 112, and 120 post-treatment, each
dog was infested with approximately 200 unfed cat fleas, C. felis felis (KS1 strain). Forty-eight hours after treatment and
48 h after each infestation, eggs were collected over a 3-h period, counted and viability determined. Dogs were
combed to remove any remaining fleas.
Results: Treatment of dogs with oral fluralaner provided a 100 % reduction in flea counts 48 h after treatment and within
48 h of every post-treatment infestation through Day122. Egg production from fluralaner treated dogs was reduced by
99.9 % (two eggs from one dog) within 48 h after treatment and not a single egg (100 % efficacy) was thereafter
collected from treated dogs. Adult flea counts and egg production from the fluralaner-treated dogs were significantly
lower than for non-treated controls at all post-treatment evaluations (P < 0.001). The two eggs collected from the single
treated dog 48 h after treatment did not produce any adult fleas. As no additional eggs were collected from treated dogs,
no viability assessment was performed.
Conclusions: A single oral dose of fluralaner flavored chews provided 100 % efficacy against repeated flea infestations
on dogs for 4 months. Fluralaner reduced egg production of activity reproducing female fleas by 99.9 % and then
killed every single female flea before any eggs could be produced following each subsequent re-infestation for the
entire 122-day evaluation period.
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The cat flea, Ctenocephalides felis felis, is well adapted
for infesting in-home environments due to its prolific
reproduction. A home can become seeded with over-
whelming numbers of life stages over the course of a few
weeks. Within 24–48 h of initiating feeding on a mam-
malian host, mating occurs and egg production begins
with each female flea rapidly filling the environment* Correspondence: lisa.math@merck.com
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lifespan that can exceed 100 days [1, 2]. These eggs then
cycle through larvae and pupae stages before emerging
as adults to begin the process anew.
Flea control management was revolutionized with the
introduction of modern topical residual flea adulticide
products such as imidacloprid and fipronil in the mid-
1990s. Since then numerous additional products have
been developed for use in various topical and, more re-
cently, oral formulations [3, 4]. These products succeed
in providing effective flea control in one of two ways; asrticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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portunity to lay eggs, and/or by negatively impacting the
viability of the eggs produced [5–7]. Successful flea con-
trol requires a residual adulticide product that persist-
ently kills newly arriving adult fleas before egg laying
begins. Success can only be achieved if the residual adul-
ticide product works for the full duration of its intended
use with 100 % efficacy, because any viable female fleas
surviving beyond 24 h can perpetuate the infestation
[5, 6]. If limited egg production occurs in spite of treat-
ment, then it may still be possible to control flea
reproduction if the product also prevents egg develop-
ment [5, 7, 8]. Under the ideal environmental conditions
often found in homes, a flea typically cycles through its life
stages over the course of 3 – 8 weeks, although this can oc-
casionally extend to 90 days or rarely longer [5, 6, 9, 10].
Thus, to eradicate an infestation successfully, effective
control must be maintained for at least 12 weeks. This
duration will lead to clean up of juvenile flea life stages in
the environment, and usually requires successful diligent
administration of 2–3 or more doses of a monthly flea
control product [5, 6, 9, 10].
Even with the availability of modern flea control prod-
ucts, fleas continue to infest the homes of dog owners,
possibly because the owners do not correctly adhere to
treatment recommendations [11] or because the residual
speed of kill of the product in use tapers off at the end
of the month permitting successful flea reproduction
[12] and continued infestation. It has been reported that
on average dog owners only administer 5.2 months of
flea and tick preventive per year [13]. This lack of com-
pliance and adherence puts dogs and owners at continu-
ous risk of flea infested homes and places dogs at
greater risk of exposure to vector borne diseases.
Fluralaner is a novel drug in the isoxazoline class re-
cently introduced in an oral formulation to companion
animal medicine for flea and tick protection in dogs
[14, 15]. It is rapidly absorbed and widely distributed
with a long half life of 12 – 15 days [16]. It appears there
is minimal if any metabolism as it is primarily excreted
unchanged in the feces [16]. Fluralaner’s safety profile
has been thoroughly evaluated, with no adverse events
noted in 8 week old puppies administered up to 5 times
(280 mg/kg) the maximum deliverable dose within the
dogs weight bracket (56 mg/kg) every 8 weeks until be-
yond the time when a steady state is achieved (2–3 ad-
ministered doses) [17]. No adverse events were noted in
MDR 1 homozygous negative collies administered three
times the recommended dose [18]. Because of its safety
profile, fluralaner can be dosed at 25–56 mg/kg which
achieves a 12 week label duration of activity against fleas
and multiple species of ticks (for example, in the US,
Ixodes scapularis, the black-legged tick, Dermacentor
variabilis, the American dog tick, and Rhipicephalussanguineus, the brown dog tick and 8 weeks against
Amblyomma americanum, the lone star tick [15, 19]).
The objective of this study was to evaluate the residual
efficacy of a single dose of fluralaner (Bravecto®, Merck
Animal Health) flavored chews administered to dogs
against adult Ctenocephalides felis felis, egg production
and the development of eggs to viable adults for
4 months.Methods
Animals and housing
Sixteen purpose bred dogs (8 male:8 female) were studied.
Physical examinations were conducted by a licensed veter-
inarian prior to the initial flea infestation and dogs were
determined to be in good health and free of any pre-
existing dermal lesions. No drugs, baths, shampoos or
pesticides were administered to the dogs during the 6-day
pre-conditioning phase or the course of the study other
than what is described in the protocol. Dogs were fed a
commercial dry ration, water was available ad libitum and
dogs were housed in individual kennels. All animal care
procedures conformed to guidelines established by the
Institutional Animal Care and Use Committee at Kansas
State University (IACUC # 3463).Animal selection and randomization
On Day −5, all dogs were infested with 100 adult cat
fleas, C. felis felis, (KS1 strain) 1 to 5 days post emer-
gence. On Day −4, flea comb counts were performed to
evaluate the susceptibility of each dog to maintain ex-
perimental infestations and for random allocation of the
dogs to the treatment groups. Each dog was combed
with a fine-toothed flea comb having 12 to 13 teeth/cm.
Flea removal was achieved by combing each dog thor-
oughly for 10 min. If five or more fleas were recovered
during this period, the dog was combed for an additional
5 min. If any fleas were recovered during the second
combing period, the dog was combed for an additional
5 min, for a maximum of 20 min. The six females and
six males with the highest flea counts were retained for
the study.
Within each gender the six dogs were ranked in de-
scending order by flea count. For each of the six dogs in
each gender group a random number generated by
EXCEL was assigned to each dog in rank order. Dogs
were grouped into replicates of two based on descending
flea counts. The two dogs within each of the replicates
were allocated to treatment groups (1 and 2). Each repli-
cate contained one dog in each of the two treatment
groups. The highest random number in each block was
assigned to treatment group 1 and the other to treat-
ment group 2. This was repeated for each block of dogs
in the study. Thus, at the end of the process, there were
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group.
Infestations and treatment
Dogs in treatment group 1 were administered a single
fluralaner flavored chew (BRAVECTO®, Merck Animal
Health) to achieve a minimum dose of at least 25 mg/kg.
Dogs were fed one hour prior to treatment and an esti-
mate was made of the amount of food consumed prior
to dosing. Dogs in treatment group 2 served as un-
treated controls. Dogs were observed following treat-
ment for any adverse events associated the treatments.
Adulticide and egg production efficacy evaluations
On Days −2, 28, 56, 84, 91, 98, 105, 112, and 120 post-
treatment, each dog was infested with approximately
200 unfed cat fleas, C. felis felis (KS1 strain). Then 48 h
after treatment and 48 h after each subsequent infest-
ation, dogs were removed from their individual kennels
and placed into individual stainless steel metabolic cages
with expanded metal floors over solid collecting pans to
conduct egg collections. Dogs were housed in these
cages for 3 h and were then brushed to dislodge any
remaining flea eggs. After this, dogs were combed to re-
move any remaining fleas- as previously described- and
returned to their individual kennels.
Once dogs were removed from the cages all flea eggs
deposited in the stainless steel pans were collected,
counted and viability of eggs determined. Eggs from
each dog (up to 100) were placed in a glass Petri dish
containing growth media (sand, ground dog chow,
brewer’s yeast and dried blood) and held in a growth
rearing chamber (Model # I30BLLC8, Percival Manufac-
turing Co., Boone, IA; 27-28 ° C, 70-80 % relative
humidity, 24 h dark). Between 10 – 12 days after egg
collection, pupae (and any larvae that had not completed
cocoon formation) were sifted from the media and
placed into plastic vials with lids. Adult emergence was
determined by counting emerged adult fleas approxi-
mately 28 days after egg collection. Personnel conduct-
ing comb counts, egg counts, egg collections and
viability assessments were blinded to treatment groups.
Data analysis
Data at each time point were analyzed separately. The
adult flea and egg count data were transformed prior to
analysis using the Y = loge(× + 1) transformation. The log
transformed data were analyzed by a mixed linear model
including treatment as the fixed effect; and block as the
random effect. Least squares means were used for treat-
ment comparisons and were back transformed to obtain
the estimates of geometric mean flea and egg counts. A
two-tailed test was used for the comparison betweengroups and significance was declared when p < 0.05. The
primary software was SAS version 9.3.
Percent control of adult fleas was calculated using
geometric means with Abbott’s formula:
Efficacy (%) = 100 × (MC - MT) / MC
Where: − MC is the geometric mean number of total
adult live fleas on untreated dogs
- MT is the geometric mean number of total adult live
fleas on treated dogs.
Efficacy was calculated using both geometric and arith-
metic means; however, geometric means were considered
as the primary approach for effectiveness evaluation.
The control of egg production was also calculated
using Abbott’s formula.
Results
On study day 0, dogs were between 7 – 7.5 months of
age, with dogs in the negative control group and flurala-
ner treatment group weighing an average of 8.6 kg
(7.4-9.7 kg) and 8.2 kg (7.5-9.0 kg), respectively. All
treatment group 1 dogs were administered a 250 mg
chewable tablet of fluralaner producing a mean dosage
of 30.8 mg/kg (27.8-33.3 mg/kg). The fluralaner treated
dogs consumed on average approximately 1 cup (0.24 L)
of dry dog food in the hour prior to dosing, with two dogs
only consuming a half (0.5) a cup (0.12 L) and the largest
amount being 2.5 cups (0.6 L) of food by one dog.
All dogs included in the study demonstrated adequate
pre-treatment flea retention with Day −4 geometric
mean flea counts in treated and control groups aver-
aging 76.0 and 78.1, respectively. Control dogs also
maintained adequate infestations throughout the post-
treatment period study with geometric mean flea counts
ranging from 47.2 – 93.9.
The administration of a single oral dose of fluralaner
produced highly significant reductions in geometric
mean flea counts on treated dogs throughout the entire
122 days of the study (P < 0.001; Table 1). Treatment
with fluralaner provided a 100 % reduction in flea counts
48 h after treatment and a 100 % reduction in flea
counts within 48 h at every post-treatment infestation of
the 122-day study (Table 1), an efficacy that was signifi-
cant (P < 0.001) at every time point.
The 3-h egg collection numbers from control dogs
were variable, but adequate throughout the study
(Table 2). Following the Day −2 infestation when eggs
were collected 48 h after treatment the geometric mean
flea egg count from controls was 171.7 (Table 2). Follow-
ing the post-treatment infestations geometric mean egg
counts from control dogs ranged from a low of 26.7 on
Day 114 to a high of 128.9 on Day 30 (Table 2).
Egg production from fluralaner treated dogs was re-
duced by 99.9 % (two eggs were collected from one dog)
within 48 h after treatment. Thereafter not a single egg
Table 1 Geometric mean flea counts and percent control against the KS1 cat flea strain 48 h post-treatment or infestation of dogs treated with fluralaner flavored chews
Day 2 Day 30 Day 58 Day 86 Day 93 Day 100 Day 107 Day 114 Day 122
Treatment1 Mean # of
fleas2,3
%
control4
Mean #
of fleas
%
control
Mean #
of fleas
%
control
Mean #
of fleas
%
control
Mean #
of fleas
%
control
Mean #
of fleas
%
control
Mean #
of fleas
%
control
Mean #
of fleas
%
control
Mean #
of fleas
%
control
Controls 93.9 75.7 78.6 47.2 55.6 62.3 54.9 54.6 52.0
Fluralaner 0.0a 100 0.0a 100 0.0a 100 0.0a 100 0.0a 100 0.0a 100 0.0a 100 0.0a 100 0.0a 100
112 dogs were used in this study. The 6 dogs in each control group received no treatment. The 6 dogs in the fluralaner group were administered an oral chewable tablet once on Day 0
2Each dog was infested with approximately 200 adult Ctenocephalides felis felis from the KS1 strain on days −2, 7, 28, 56, 84, 91, 105, 112 and 120 post-treatment
3Geometric mean # of live fleas recovered from dogs per treatment group
4 % control = ((geometric mean count control -geometric mean count treatment)/ geometric mean count treatment)) × 100
ageometric mean of treatment group was significantly different from control (P <0.001)
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Table 2 Geometric mean egg counts and percent control against the KS1 cat flea strain 48 h post-treatment or infestation of dogs treated with fluralaner flavored chews
Day 2 Day 30 Day 58 Day 86 Day 93 Day 100 Day 107 Day 114 Day 122
Treatment1 Mean # of
eggs2,3
%
control4
Mean #
of eggs
%
control
Mean #
of eggs
%
control
Mean #
of eggs
%
control
Mean #
of eggs
%
control
Mean #
of eggs
%
control
Mean #
of eggs
%
control
Mean #
of eggs
%
control
Mean #
of eggs
%
control
Controls 171.7 128.9 83.9 67.1 87.4 53.8 64.4 26.7 67.4
Fluralaner 0.2a 99.9 0.0a 100 0.0a 100 0.0a 100 0.0a 100 0.0a 100 0.0a 100 0.0a 100 0.0a 100
112 dogs were used in this study. The 6 dogs in each control group received no treatment. The 6 dogs in the fluralaner group were administered an oral chewable tablet once on Day 0
2Each dog was infested with approximately 200 adult Ctenocephalides felis felis from the KS1 strain on days −2, 7, 28, 56, 84, 91, 105, 112 and 120 post-treatment, flea eggs were collected 48 h post-treatment or post-
infestation during a 3-h collection period
3Geometric mean # of eggs recovered from dogs per treatment group
4 % control = ((geometric mean count control -geometric mean count treatment)/ geometric mean count treatment)) x 100
ageometric mean of treatment group was significantly different from control (P ≤0.001)
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the remainder of the 122-day study (Table 2). Egg pro-
duction from the fluralaner-treated dogs was signifi-
cantly lower than those for non-treated controls at all
post-treatment evaluations (P < 0.001, Table 2).
The two eggs collected from the single fluralaner
treated dog 48 h after treatment did not produce any
adult fleas. Thereafter, because there were no eggs col-
lected from any treated dog no assessment of egg viabil-
ity from fluralaner treated dogs could be performed.
Eggs from control dogs were viable with adult emer-
gence always ≥46.6 % for the entire 122-day study.
There were no product related or serious adverse
events observed in either the treated or control dogs.
Discussion
An effective flea adulticide should have sufficient re-
sidual speed of flea kill to rapidly eliminate most if not
all the newly emerging fleas that jump onto the treated
pet between labeled administration periods. If a flea
product kills those fleas before eggs are laid or has an
ovicidal effect upon any eggs produced by any female
flea surviving the adulticide, that product would mark-
edly suppress the reproductive success of a flea popula-
tion [7, 20].
Most currently available residual topical spot-on and
systemic insecticide formulations are labelled to provide
30 days of effective flea control. Whereas, a single oral
administration of fluralaner provided 100 % control of
adult C. felis felis on dogs for at least 120 days after
treatment. The efficacy duration achieved in this study
was a month beyond the labeled reapplication period of
84 days and this study did not reach the end point where
fleas could survive long enough to reproduce.
The first flea infestation was applied 48 h before the
initial treatment. Therefore, some flea egg production is
to be expected at the start of the study. However, within
48 h of fluralaner administration, egg production almost
completely halted (99.9 % reduction), and those remark-
ably few (two) eggs were not viable. Not a single egg was
laid by fleas on treated dogs for the next 4 months.
Based on this longevity of residual adulticide activity
veterinarians should expect that a single oral administra-
tion of a fluralaner chewable tablet would eliminate the
existing flea infestation on a dog, continue to kill newly
acquired fleas and that egg production should be virtu-
ally non-existent for the next 120 days.
Consumption of blood is necessary before C. felis felis
can initiate reproduction and egg production does not
begin until 24–48 h after females take their first blood
meal [1, 2]. Therefore, if a residual insecticide can kill
newly acquired fleas within 24 h, egg production should
be markedly reduced or halted. While this study did not
specifically evaluate the residual speed of kill offluralaner, it did demonstrate that following re-
infestations from Day 7 through Day 120, fluralaner
killed every female flea before any eggs were produced.
Proper administration of a single dose of fluralaner to
dogs in a flea infested home would therefore be expected
to effectively drive the flea population to extinction. All
dogs and all cats in the household must be treated ap-
propriately in order to completely shut down flea
reproduction and achieve this effective control. Because
fluralaner is not approved for use in cats, another effect-
ive flea control product must be chosen for cats in the
household.
Egg production from untreated controls proved to be
highly variable in this study, a finding that was not com-
pletely unexpected. Flea egg collection from dogs is not
as straight forward as from cats, due to fecal and urine
elimination by kenneled or caged dogs. Therefore, an
egg collection method was used in this study involving
collection for a 3-h interval based on a prior report [21]
and proved successful for valid assessment in this study.
The short collection interval minimizes potential fecal
and urine contamination and, given the high reproduct-
ive output of C. felis felis should provide adequate num-
bers of eggs to allow for statistical comparisons of
treated and untreated groups. Even then some minimal
urine and fecal contamination can still occur and result
in some eggs not being collected, counted or available
for viability assessments.
This study was conducted using the KS1 flea strain.
Several previous studies have demonstrated that this
strain has reduced susceptibility or outright resistance to
carbaryl, chlorpyriphos, fenthion, fipronil, imidacloprid,
permethrin, pyrethrins, and spinosad [20, 22–27].
Efficacy studies evaluating various formulations of
fipronil have consistently demonstrated that the 30 day
residual efficacy of fipronil has been consistently less
than 90 % against the KS1 flea strain [22, 23, 28]. The
present study showed that the KS1 flea strain is clearly
susceptible to fluralaner. Therefore, this study further
verifies previous in vitro research demonstrating a
unique fluralaner binding site that differs from fipronil,
thereby renewing interest in GABA Chloride channel
antagonists as effective means of flea control [29].
Conclusions
A single oral dose of fluralaner flavored chews provided
100 % efficacy against repeated flea infestations on dogs
for 4 months. Fluralaner rapidly reduced egg production
of actively reproducing female fleas and then killed every
single female flea before any eggs could be produced
following each subsequent re-infestation for the entire
122-day evaluation period. Given the effect fluralaner
had on adult fleas and egg production; it appears this
treatment can interrupt flea reproduction for at least
Dryden et al. Parasites & Vectors  (2015) 8:364 Page 7 of 74 months after a single treatment and should be able to
eliminate an existing flea infestation on dogs and in their
in-home premises. The flea reproductive breakpoint was
not reached in 122 days following a single fluralaner
treatment.
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